Comparative Pharmacology
Head-to-head clinical analysis: CLORAZEPATE DIPOTASSIUM versus XANAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLORAZEPATE DIPOTASSIUM versus XANAX.
CLORAZEPATE DIPOTASSIUM vs XANAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on gamma-aminobutyric acid type A (GABAA) receptors, enhancing GABA-mediated chloride ion influx, leading to neuronal hyperpolarization and decreased excitability.
Alprazolam is a benzodiazepine that binds to the gamma-aminobutyric acid (GABA)-A receptor at the α1, α2, α3, and α5 subunits, enhancing the effect of GABA by increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of neurotransmission.
15-60 mg/day orally in divided doses 2-4 times daily; usual starting dose 15 mg at bedtime or 15 mg twice daily.
Initial: 0.25-0.5 mg orally 3 times daily; maximum: 4 mg/day in divided doses. For panic disorder: 0.5-1 mg at bedtime or 0.5 mg 3 times daily; titrate as needed up to 10 mg/day.
None Documented
None Documented
40-50 hours (clorazepate is a prodrug rapidly converted to nordiazepam); effective half-life of nordiazepam is 40-100 hours. Accumulation occurs with repeated dosing, leading to prolonged sedation in elderly or hepatic impairment.
Terminal elimination half-life: 11.2 hours (range 6.3–26.9 hours). With repeated dosing, half-life may prolong slightly; clinical context: allows once-daily dosing for most patients.
Primarily renal (60-70% as oxazepam glucuronide and other metabolites), with 15-20% biliary/fecal elimination. Less than 1% excreted unchanged.
Renal: ~80% (mainly as glucuronide metabolites, <20% unchanged). Fecal: <7%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine